Actovegin and antibiotics compatibility. Actovegin - instructions for use, reviews, analogs and forms of release (tablets, injections in ampoules for injection, ointment, gel and cream) drugs for the treatment of metabolic disorders of the brain in adults, children (new

Name:

Name: Actovegin (Actovegin)

Pharmachologic effect:
Actovegin activates cellular metabolism (metabolism) by increasing the transport and accumulation of glucose and oxygen, enhancing their intracellular utilization. These processes lead to an acceleration of the metabolism of ATP (adenosine triphosphoric acid) and an increase in the energy resources of the cell. Under conditions that limit the normal functions of energy metabolism (hypoxia / insufficient supply of oxygen to the tissue or impaired absorption /, lack of substrate) and with increased energy consumption (healing, regeneration / tissue repair /), actovegin stimulates the energy processes of functional metabolism (the process of metabolism in body) and anabolism (the process of assimilation of substances by the body). The secondary effect is increased blood supply.

All about Actovegin: production, application, mechanism of action on the human body

Indications for use:
Insufficiency of cerebral circulation, ischemic stroke (insufficient supply of oxygen to the brain tissue due to acute cerebrovascular accident); traumatic brain injury; violations of peripheral circulation (arterial, venous); angiopathy (impaired vascular tone); trophic disorders (malnutrition of the skin) with varicose veins of the lower extremities (changes in the veins characterized by an uneven increase in their lumen with the formation of a protrusion of the wall due to a violation of the function of their valvular apparatus); ulcers of various origins; bedsores (tissue necrosis caused by prolonged pressure on them due to lying down); burns; prevention and treatment of radiation injuries. Damage to the cornea (the transparent membrane of the eye) and sclera (the opaque membrane of the eye): corneal burn (acids, alkali, lime); corneal ulcers of various origins; keratitis (inflammation of the cornea), including after transplantation (transplantation) of the cornea; corneal abrasions in patients with contact lenses; prevention of lesions in the selection of contact lenses in patients with dystrophic processes in the cornea (for the use of eye jelly), also to accelerate the healing of trophic ulcers (slowly healing skin defects), bedsores (tissue necrosis caused by prolonged pressure on them due to lying), burns, radiation skin lesions, etc.

Actovegin side effects:
Allergic reactions: urticaria, a feeling of a rush of blood, sweating, an increase in body temperature. Itching, burning in the area of application of the gel, ointment or cream; when using an eye gel - lacrimation, injection of the sclera (reddening of the sclera).

Actovegin method of administration and doses:
Doses and route of administration depend on the type and severity of the course of the disease. The drug is administered orally, parenterally (bypassing the digestive tract) and topically.
Inside designate 1-2 pills 3 times a day before meals. Dragee is not chewed, washed down with a small amount of water.
For intravenous or intra-arterial administration, depending on the severity of the disease, the initial dose is 10-20 ml. Then appoint 5 ml intravenously slowly or intramuscularly, 1 time per day every day or several times a week. 250 ml of solution for infusion is injected intravenously at a rate of 2-3 ml per minute 1 time per day every day or several times a week. You can also use 10, 20 or 50 ml of injection diluted in 200-300 ml of glucose or saline. In total, the course of treatment is 10-20 infusions. It is not recommended to add other products to the infusion solution.
Parenteral administration of actovegin should be carried out with caution due to the possibility of developing an anaphylactic (allergic) reaction. Trial injections are recommended, while it is necessary to provide conditions for emergency therapy. No more than 5 ml can be administered intravenously, since the solution has hypertonic properties (the osmotic pressure of the solution is higher than the osmotic pressure of the blood). When using the product intravenously, it is recommended to monitor the indicators of water and electrolyte metabolism.
Local application. The gel is prescribed for the cleansing and treatment of open wounds and ulcers. For burns and radiation injuries, the gel is applied to the skin with a thin layer. In the treatment of ulcers, the gel is applied to the skin in a thicker layer and covered with a compress with actovegin ointment in order to prevent sticking to the wound. Bandages are changed once a week; with strongly weeping ulcers - several times a day.
The cream is used to improve wound healing, also weeping wounds. Used in the aftermath of the formation of bedsores and the prevention of radiation injuries.
The ointment is applied in a thin layer to the skin. It is used for long-term treatment of wounds and ulcers in order to accelerate their epithelization (healing) after gel or cream therapy. For the prevention of bedsores, the ointment must be applied to the appropriate areas of the skin. To prevent radiation damage to the skin, the ointment should be applied after exposure or in between sessions.
Eye gel, 1 drop of gel is squeezed directly from the tube into the affected eye. Apply 2-3 times a day. After opening the package, the eye gel can be used for no more than 4 weeks.

In this article, you can read the instructions for using the drug Actovegin. Reviews of site visitors - consumers of this medicine, as well as opinions of doctors of specialists on the use of Actovegin in their practice are presented. We kindly ask you to actively add your reviews about the drug: the medicine helped or did not help get rid of the disease, what complications and side effects were observed, perhaps not declared by the manufacturer in the annotation. Analogues of Actovegin in the presence of existing structural analogues. Use for the treatment of metabolic and vascular disorders of the brain, tissue trophism, burns and bedsores, diabetic polyneuropathy in adults, children (including newborns), as well as during pregnancy and lactation.

Actovegin- antihypoxant, is a gemoderivate, which is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons penetrate).

Actovegin increases the concentrations of ATP, ADP, phosphocreatine, as well as amino acids (glutamate, aspartate) and GABA.

The effect of Actovegin on oxygen uptake and utilization, as well as insulin-like activity with stimulation of glucose transport and oxidation, are significant in the treatment of diabetic polyneuropathy.

In patients with diabetes mellitus and diabetic polyneuropathy, Actovegin significantly reduces the symptoms of polyneuropathy (stabbing pain, burning sensation, paresthesia, numbness of the lower extremities). Objectively, sensitivity disorders are reduced, the mental well-being of patients improves.

The effect of Actovegin begins to appear no later than 30 minutes (10-30 minutes) after parenteral administration and reaches a maximum, on average, after 3 hours (2-6 hours).

Compound

Deproteinized hemoderivat from calf blood (Actovegin concentrate or granulate) + excipients.

Pharmacokinetics

Using pharmacokinetic methods, it is impossible to study the pharmacokinetic characteristics (absorption, distribution, excretion) of the active components of Actovegin, since it consists only of physiological components that are usually present in the body.

To date, no decrease in the pharmacological efficacy of hemoderivatives has been found in patients with altered pharmacokinetics (including with hepatic or renal insufficiency, metabolic changes associated with advanced age, due to the peculiarities of metabolism in newborns).

Indications

metabolic and vascular disorders of the brain (including ischemic stroke, traumatic brain injury);
peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers);
diabetic polyneuropathy;
wound healing (ulcers of various etiologies, trophic disorders /bedsores/, burns, impaired wound healing processes);
prevention and treatment of radiation damage to the skin and mucous membranes during radiation therapy.

Release form

Film-coated tablets 200 mg.

Solution for injections (injections) 40 mg/ml in ampoules of 5 ml and 10 ml.

Ointment for external use 5% (not supplied to Russia).

Cream for external use 5% (not supplied to Russia).

Gel for external use 20% (not supplied to Russia).

Instructions for use and dosage

Pills

Assign inside 1-2 tablets 3 times a day before meals. The tablet is not chewed, washed down with a small amount of water. The duration of treatment is 4-6 weeks.

Ampoules

The solution for injection is administered intra-arterially, intravenously (including as an infusion or dropper) and intramuscularly. The infusion rate is about 2 ml / min. In connection with the potential for the development of anaphylactic reactions, it is recommended to test for the presence of hypersensitivity to the drug before infusion.

The duration of the course of treatment is determined individually, depending on the symptoms and severity of the disease.

Metabolic and vascular disorders of the brain: from 5 to 25 ml (200 - 1000 mg per day) intravenously daily for two weeks, followed by the transition to a tablet form.

Ischemic stroke: 20-50 ml (800-2000 mg) in 200-300 ml of 0.9% sodium chloride solution or 5% dextrose solution intravenously daily for 1 week, then 10-20 ml (400-800 mg ) intravenously drip - 2 weeks, followed by the transition to a tablet form.

Peripheral (arterial and venous) vascular disorders and their consequences: 20-30 ml (800-1000 mg) of the drug in 200 ml of 0.9% sodium chloride solution or 5% dextrose solution intra-arterially or intravenously daily; the duration of treatment is 4 weeks.

Diabetic polyneuropathy: 50 ml (2000 mg) per day intravenously for 3 weeks, followed by the transition to a tablet form - 2-3 tablets 3 times a day for at least 4-5 months.

Wound healing: 10 ml (400 mg) intravenously or 5 ml intramuscularly daily or 3-4 times a week, depending on the healing process (in addition to local treatment with Actovegin in dosage forms for external use).

Prevention and treatment of radiation damage to the skin and mucous membranes during radiation therapy: the average dose is 5 ml (200 mg) intravenously daily during breaks in radiation exposure.

Radiation cystitis: 10 ml (400 mg) daily transurethral in combination with antibiotic therapy.

Side effect

skin rash;
skin hyperemia;
hyperthermia;
hives;
swelling;
medicinal fever;
anaphylactic shock.

Contraindications

decompensated heart failure;
pulmonary edema;
oliguria, anuria;
fluid retention in the body;
hypersensitivity to the components of the drug;
hypersensitivity to similar drugs.

Use during pregnancy and lactation

The use of the drug during pregnancy did not adversely affect the mother or fetus, however, if necessary, the use of the drug during pregnancy should take into account the potential risk to the fetus. So the use of Actovegin in these cases requires caution.

special instructions

In connection with the potential for the development of anaphylactic reactions, it is recommended to conduct a test (trial injection of 2 ml / m) before infusion.

In the case of an intramuscular route of administration, the drug should be administered slowly in an amount of not more than 5 ml.

Actovegin solutions have a slightly yellowish tint. The color intensity may vary from one batch to another depending on the characteristics of the starting materials used, but this does not affect the effectiveness and tolerability of the drug.

Do not use an opaque solution or a solution containing particles.

With repeated injections, the water-electrolyte balance of the blood plasma should be monitored.

After opening the ampoule or vial, the solution cannot be stored.

drug interaction

Drug interaction of the drug Actovegin has not been established.

However, in order to avoid possible pharmaceutical incompatibility, it is not recommended to add other drugs to Actovegin infusion solution.

Analogues of the drug Actovegin

The drug Actovegin has no structural analogues for the active substance.

Analogues by pharmacological group (antihypoxants and antioxidants):

Actovegin granulate;
Actovegin concentrate;
Antisten;
Astrox;
Vixipin;
Vitanam;
Hypoxen;
Glation;
Deprenorm;
Dihydroquercetin;
Dimephosphone;
Cardioxipin;
Carditrim;
Carnitine;
Carnifit;
Kudevita;
Kudesan;
Kudesan for children;
Kudesan Forte;
Levocarnitine;
Limontar;
Meksidant;
Mexidol;
Mexidol solution for injections 5%;
Mexicor;
Mexipridol;
Mexiprim;
Mexifin;
Methylethylpyridinol;
Metostabil;
Sodium hydroxybutyrate;
Neurox;
Neurolipon;
Octolipen;
Olifen;
Predizin;
Preductal;
Rexod;
Rimecor;
Solcoseryl;
Thiogamma;
Thiotriazoline;
Trekrezan;
Triducard;
Trimectal;
Trimetazidine;
Phenosanoic acid;
Cerecard;
Cytochrome C;
Eltacin;
Emoxybel;
Emoxipin;
Enerlit;
Yantavit.

In the absence of analogues of the drug for the active substance, you can follow the links below to the diseases that the corresponding drug helps with and see the available analogues for the therapeutic effect.

Name:

Actovegin (Actovegin)

Pharmacological
action:

Actovegin activates cellular metabolism (metabolism) by increasing the transport and accumulation of glucose and oxygen, enhancing their intracellular utilization.
These processes lead to acceleration of ATP metabolism(adenosine triphosphoric acid) and increase the energy resources of the cell. Under conditions that limit the normal functions of energy metabolism (hypoxia / insufficient supply of oxygen to the tissue or impaired absorption /, lack of substrate) and with increased energy consumption (healing, regeneration / tissue repair /), actovegin stimulates the energy processes of functional metabolism (the process of metabolism in body) and anabolism (the process of assimilation of substances by the body). The secondary effect is increased blood supply.

Indications for
application:

Indications for use:
- cerebrovascular insufficiency, ischemic stroke (insufficient supply of oxygen to the brain tissue due to acute cerebrovascular accident);
- traumatic brain injury; violations of peripheral circulation (arterial, venous);
- angiopathy (impaired vascular tone);
- trophic disorders (malnutrition of the skin) with varicose veins of the lower extremities (changes in the veins characterized by an uneven increase in their lumen with the formation of a protrusion of the wall due to a violation of the function of their valvular apparatus);
- ulcers of various origins; bedsores (tissue necrosis caused by prolonged pressure on them due to lying down);
- burns;
- prevention and treatment of radiation injuries.

Corneal damage(transparent membrane of the eye) and sclera(opaque shell of the eye):
- burn of the cornea (acids, alkali, lime);
- corneal ulcers of various origins;
- keratitis (inflammation of the cornea), including after transplantation (transplantation) of the cornea;
- abrasions of the cornea in patients with contact lenses;
- prevention of lesions during the selection of contact lenses in patients with dystrophic processes in the cornea (for the use of eye jelly), as well as to accelerate the healing of trophic ulcers (slowly healing skin defects), bedsores (tissue necrosis caused by prolonged pressure on them due to lying), burns , radiation damage to the skin, etc.

Mode of application:

In / a, in / in(including in the form of infusion), i/m, transurethral.

In connection with the potential for the development of anaphylactic reactions, it is recommended to test for the presence of hypersensitivity to the drug before infusion.

Ischemic stroke. 250-500 ml solution for infusion (1000-2000 mg of the drug) per day i.v. for 2 weeks or 20-50 ml of solution for injection (800-2000 mg of the drug) in 200-300 ml of 0.9% sodium chloride or 5% dextrose solution IV drip for 1 week, then 10-20 ml (400-800 mg of the drug) IV drip for 2 weeks. Then - the transition to the tablet form.

Metabolic and vascular disorders of the brain. 250-500 ml of solution for infusion (1000-2000 mg of the drug) per day or 5-25 ml of solution for injection (200-1000 mg of the drug) per day intravenously for 2 weeks, followed by the transition to a tablet form.

Peripheral (arterial and venous) vascular disorders and their consequences. 250 ml (1000 mg) solution for infusion in / a or in / in daily or several times a week, followed by the transition to a tablet form. 20-30 ml solution for injection (800-1200 mg of the drug) in 200 ml of 0.9% sodium chloride solution or 5% dextrose solution intravenously or intravenously daily for 4 weeks.

Diabetic polyneuropathy. 250-500 ml of solution for infusion or 50 ml of solution for injection (2000 mg of the drug) per day intravenously for 3 weeks, followed by the transition to a tablet form.

Wound healing. 250 ml solution for infusion (1000 mg of the drug) IV daily or several times a week, depending on the rate of healing. 10 ml solution for injection (400 mg of the drug) IV or 5 ml IM daily or 3-4 times a week, depending on the rate of healing. Joint use with dosage forms of Actovegin® for external use is possible.

Prevention and treatment of radiation injuries of the skin and mucous membranes. 250 ml solution for infusion (1000 mg of the drug) intravenously the day before and daily during radiation therapy, as well as within 2 weeks after its completion, followed by the transition to a tablet form. The rate of administration is about 2 ml/min. 5 ml solution for injection (200 mg) IV daily during breaks in radiation exposure.

Radiation cystitis. Transurethral, 10 ml injection (400 mg of the drug) in combination with antibiotic therapy. The rate of administration is about 2 ml/min.

The duration of the course of treatment is determined individually according to the symptoms and severity of the disease.

Instructions for use of ampoules with a break point

1. Place the tip of the ampoule with the breaking point up.
2. Gently tapping with your finger and shaking the ampoule, allow the solution to flow down from the tip of the ampoule.
3. Break off the tip of the ampoule at the break point by moving away from you.

Side effects:

Allergic reactions (skin rash, skin flushing, hyperthermia), up to anaphylactic shock.

Catad_pgroup Tissue repair (regeneration) stimulators

Actovegin injection solution - instructions for use

Registration number:

Trade name of the drug:

Actovegin ®

Group name

Deproteinized calf blood hemoderivat

Dosage form:

injection

Compound

For 2 ml ampoules:

1 ampoule contains:
current substance: Actovegin® concentrate (in terms of dry deproteinized hemoderivative blood of calves) 1) - 80.0 mg;
auxiliary substance: water for injection - up to 2 ml.

For 5 ml ampoules:

1 ampoule contains:
current substance: Actovegin® concentrate (in terms of dry deproteinized hemoderivative blood of calves) 1) - 200.0 mg;
auxiliary substance: water for injection - up to 5 ml.

For 10 ml ampoules:

1 ampoule contains:
current substance: Actovegin® concentrate (in terms of dry deproteinized hemoderivative blood of calves) 1) - 400.0 mg;
auxiliary substance: water for injection - up to 10 ml.

1) Actovegin® concentrate contains sodium chloride in the form of sodium and chloride ions, which are components of the blood of calves. Sodium chloride is not added or removed during the production of the concentrate. The content of sodium chloride is about 53.6 mg (for 2 ml ampoules), about 134.0 mg (for 5 ml ampoules) and about 268.0 mg (for 10 ml ampoules).

Description:

clear yellowish solution

Pharmacotherapeutic group:

tissue regeneration stimulator

ATX code:

pharmachologic effect

Pharmacodynamics

Antihypoxant. Actovegin® is a hemoderivate, which is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons pass).

It has a positive effect on the transport and utilization of glucose, stimulates oxygen consumption (which leads to stabilization of the plasma membranes of cells during ischemia and a decrease in lactate formation), thus having an antihypoxic effect, which begins to manifest itself no later than 30 minutes after parenteral administration and reaches a maximum on average after 3 hours (2-6 hours). Actovegin® increases the concentration of adenosine triphosphate, adenosine diphosphate, phosphocreatine, as well as amino acids - glutamate, aspartate and gamma-aminobutyric acid.

The effect of Actovegin® on oxygen uptake and utilization, as well as insulin-like activity with stimulation of glucose transport and oxidation, are significant in the treatment of diabetic polyneuropathy (DPN). In patients with diabetes mellitus and diabetic polyneuropathy, Actovegin® significantly reduces the symptoms of polyneuropathy (stabbing pain, burning sensation, paresthesia, numbness in the lower extremities). Sensitivity disorders are objectively reduced, and the mental well-being of patients improves.

Pharmacokinetics

Using pharmacokinetic methods, it is impossible to study the pharmacokinetic parameters of Actovegin®, since it consists only of physiological components that are usually present in the body.

To date, no decrease in the pharmacological effect of hemoderivatives has been found in patients with altered pharmacokinetics (for example, hepatic or renal insufficiency, metabolic changes associated with advanced age, as well as metabolic features in newborns)

Indications

Metabolic and vascular disorders of the brain (including ischemic stroke, traumatic brain injury).
Peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers); diabetic polyneuropathy
Wound healing (ulcers of various etiologies, burns, trophic disorders (bedsores), impaired wound healing processes).
Prevention and treatment of radiation damage to the skin and mucous membranes during radiation therapy

Contraindications

Hypersensitivity to Actovegin® or similar drugs, decompensated heart failure, pulmonary edema, oliguria, anuria, fluid retention in the body.

WITH caution: hyperchloremia, hypernatremia

Use during pregnancy and lactation:

the use of the drug in pregnant women did not cause negative effects on the mother or fetus. However, when used in pregnant women, the potential risk to the fetus must be considered.

Dosage and administration

Intra-arterially, intravenously (including in the form of infusion) and intramuscularly. In connection with the potential for the development of anaphylactic reactions, it is recommended to test for the presence of hypersensitivity to the drug before infusion.

Instructions for using ampoules with a break point:

Position the tip of the ampoule point up! Gently tapping with your finger and shaking the ampoule, allow the solution to flow down from the tip of the ampoule.

Depending on the severity of the clinical picture, the initial dose is 10-20 ml / day intravenously or intra-arterially; then 5 ml intravenously or 5 ml intramuscularly.
When administered in the form of an infusion, 10-20 ml of ACTOVEGIN© is added to 200-300 ml of the stock solution (0.9% sodium chloride solution or 5% dextrose solution). Injection rate: about 2 ml/min.
Metabolic and vascular disorders of the brain: at the beginning of treatment, 10 ml intravenously daily for two weeks, then 5-10 ml intravenously 3-4 times a week for at least 2 weeks.
Ischemic stroke: 20-50 ml in 200-300 ml of the stock solution intravenously drip daily for 1 week, then 10-20 ml intravenously drip - 2 weeks.
Peripheral (arterial and venous) vascular disorders and their consequences: 20-30 ml of the drug in 200 ml of the stock solution intra-arterially or intravenously daily; the duration of treatment is about 4 weeks.
Wound healing: 10 ml intravenously or 5 ml intramuscularly daily or 3-4 times a week, depending on the healing process (in addition to local treatment with ACTOVEGIN© in topical dosage forms).
Prevention and treatment of radiation damage to the skin and mucous membranes during radiation therapy: the average dose is 5 ml intravenously daily during breaks in radiation exposure.
Radiation cystitis: daily 10 ml transurethral in combination with antibiotic therapy.

Side effect

Allergic reactions (skin rash, skin flushing, hyperthermia) up to anaphylactic shock.

Interaction with other drugs

Currently unknown.

special instructions
In the case of an intramuscular route of administration, slowly inject no more than 5 ml. Due to the possibility of an anaphylactic reaction, a trial injection (2 ml intramuscularly) is recommended.
The solution for injection has a slightly yellowish tint. The color intensity may vary from one batch to another depending on the characteristics of the starting materials used, but this does not adversely affect the activity of the drug or its tolerability.
Do not use a solution that is opaque or contains particles.
After opening the ampoule, the solution can not be stored.

Release form

Solution for injections 40 mg/ml.
2, 5, 10 ml of the drug in colorless glass ampoules (type I, Eur. Pharm.) with a break point. 5 ampoules in a plastic blister pack. 1 or 5 blister packs with instructions for use are placed in a cardboard box. Transparent protective stickers of a round shape with holographic inscriptions and control of the first opening are pasted on the pack.

Best before date

5 years. Do not use after the expiration date.

Storage conditions

At a temperature not exceeding 25 ° C in a place protected from light. Keep out of the reach of children!

Terms of dispensing from pharmacies

By prescription.

Manufacturer
"Nycomed Austria GmbH", Austria
Art. Peter Strasse 25, A-4020 Linz, Austria
"Nycomed Austria GmbH", Austria
St. Peter Strasse 25, A-4020 Linz, Austria

Consumer complaints should be directed to:
Takeda Pharmaceuticals Limited Liability Company (Takeda Pharmaceuticals LLC)

), Actovegin has an antihypoxic (improves the utilization of oxygen by the body) effect, which manifests itself 30 minutes after parenteral administration, reaching a maximum after 2-6 hours.

Parenteral administration of drugs is a method of introducing drugs into the body, in which they bypass the gastrointestinal tract. Parenteral administration of the drug is carried out using injections (injections in ampoules) and infusion therapy (intravenous administration of a solution for infusion).

Actovegin has an antihypoxic, antioxidant, wound-healing effect, stimulates the processes of functional metabolism (metabolism in the body) and anabolism (absorption of substances by the body). The drug improves blood microcirculation in the vessels of the legs, starting the process of tissue regeneration when their nutrition suffers from damage to the veins (chronic venous insufficiency, thrombophlebitis, varicose veins).

Actovegin increases the concentration of phosphocreatine (creatine phosphoric acid), adenosine diphosphate (ADP), adenosine triphosphate (ATP), amino acids gamma-aminobutyric acid, aspartate (aspartic acid), glutamate (glutamic acid).

Actovegin is used for diseases of the heart and blood vessels, lesions of the central nervous system, for injuries, ulcers. The versatility of the remedy is due to the fact that Actovegin increases the transport of glucose and oxygen to the cells of organs, enhancing their energy resources, increasing functional abilities and survival in conditions where oxygen supply is insufficient and cells are unable to fully function. By facilitating the active entry of glucose into cells, Actovegin has an effect. The agent is an important component of the therapy of patients with diabetes mellitus, including the treatment of diabetic polyneuropathy (DPN).

Diabetic polyneuropathy is characterized by damage to the human nervous system, develops in people suffering from diabetes mellitus due to consistently high blood sugar (glucose) (hyperglycemia). The most significant mechanisms for the development of DPN are ischemia and metabolic disorders in the nerve.

The use of Actovegin reduces the symptom of DPN in the form of paresthesia (burning, tingling, crawling, numbness in the lower extremities).

Taking Actovegin helps to reduce sensitivity disorders, improve the mental well-being of the patient.

The duration of the course of treatment with Actovegin is determined by the doctor individually according to the symptoms and severity of the disease.

Anatomical Therapeutic Chemical Classification (ATC)

Anatomical-therapeutic-chemical classification (anatomical-therapeutic-chemical, ATC) is an international classification system for medicines. The main purpose of ATC is to provide statistical data on the consumption of medicines.

According to the ATC, Actovegin drugs, depending on the form of release, belong to the following groups:

Tablets (dragged), solution for infusion, solution for injection in ampoules - B06AB Other blood preparations,
Gel, creams and ointments for external use - D11AX Other preparations for the treatment of skin diseases,
Eye gel - S01X Other drugs for the treatment of diseases of the eyes (currently not assigned a code).

Pharmacological group

Actovegin, a drug that activates tissue metabolism, improves trophism and stimulates the regeneration process, belongs to the following pharmacological groups, depending on the form of release.

Actovegin tablets, infusion solution and injection solution in ampoules:

angioprotectors and microcirculation correctors,
regenerants and reparants.

At the molecular level, Actovegin promotes an increase in oxygen consumption and utilization (increases resistance to hypoxia), increases energy metabolism and glucose consumption.

Nosological classification (ICD-10)

The Tenth Revision International Classification of Diseases (ICD-10) is a standard assessment tool in the field of health management, medicine, epidemiology, and analysis of the general health of the population. According to ICD-10, the drug Actovegin, depending on the form, can be used for the following diseases and conditions.

Actovegin coated tablets:

F03 Dementia, unspecified
I73 Other peripheral vascular diseases,
S06 Intracranial injury.

Actovegin gel, cream and ointment for external use:

L90.8 Other atrophic changes in skin
L98.4 Chronic skin ulcer, not elsewhere classified
L98.4.2* Skin ulcer, trophic,
T14.0 Superficial injury of body region unspecified
Z100* CLASS XXII Surgical practice.

Infusion solution and injection solution in ampoules Actovegin:

I63 Cerebral infarction,
I25.2 Past myocardial infarction,
I67.9 Cerebrovascular disease, unspecified
I69 Sequelae of cerebrovascular diseases,
I73.9 Peripheral vascular disease, unspecified
I79.2 Peripheral angiopathy in diseases classified elsewhere
I87.2 Venous insufficiency (chronic) (peripheral)
I99 Other and unspecified disorders of the circulatory system,
L58 Radiation dermatitis, radiation,
L89 Decubital ulcer (traumatic ulcer, bed sore),
L98.4.2* Skin ulcer, trophic,
S06 Intracranial injury,
T14.1 Open wound of body region unspecified
T30 Thermal and chemical burns, unspecified
T79.3 Post-traumatic wound infection, not elsewhere classified

The term "specified" disease (condition) is used in cases where the doctor has a complete package of medical documents that allow the most objective assessment of the development of the disease (condition). In a situation where this set of documents is missing, and it is impossible to determine the course of the disease by the state of the internal organs, the diagnosis is made. unspecified».

Composition Actovegin

As part of the drug Actovegin, as an active substance, there is deproteinized hemoderivative of calf blood, obtained by means of ultrafiltration (compounds with a molecular weight of less than 5000 daltons pass), containing exclusively physiological substances.

1 tablet (dragee) contains 200 mg,
1 gram of gel for external use contains 8 mg,
1 gram of topical cream contains 2 mg,
1 gram of ointment for external use contains 2 mg,
1 ml solution for injection contains 40 mg,
1 ml solution for infusion contains 4 mg (in a 10% solution) or 8 mg (in a 20% solution),
1 gram of eye gel contains 8 mg.

Auxiliary substances in the composition tablets Actovegin are:

magnesium stearate,
povidone-K90,
talc.

As part of shells Actovegin tablets additionally present:

mountain glycol wax,
gum arabic (acacia gum),
diethyl phthalate,
dye quinoline yellow varnish aluminum,
macrogol-6000,
titanium(IV) oxide (titanium dioxide),
povidone-K30,
sucrose,
talc,
hypromellose phthalate.

The composition of the cream for external use additionally contains benzalkonium chloride 0.2 mg per 1 gram of the drug.

Excipients in the composition of the infusion solution of Actovegin and the drug in the form of ampoules with a solution for injection are sodium chloride and water for injection. The solution for infusion in a dextrose solution additionally contains dextrose.

Release form and dosage Actovegin

The drug Actovegin is available in the form of tablets (pellets), gel, cream, ointment, ampoules for injection, solution for infusion, ophthalmic gel.

Actovegin coated tablets (dragees):

tablets in a bottle of 200 mg, No. 10,
tablets in a bottle of 200 mg, No. 30,
tablets in a bottle of 200 mg, No. 50,
tablets in a bottle of 200 mg, No. 100.

Packing of tablets (drops) includes:

bottle (vial) of dark glass with a screw neck, sealed with an aluminum cap with first opening control, containing round biconvex shiny tablets, coated greenish-yellow color,
a cardboard pack with a pasted transparent protective sticker of a round shape with holographic inscriptions and control of the first opening.

Actovegin gel for external use:

gel in a tube 20%, 20 grams,
gel in a tube 20%, 30 grams,
gel in a tube 20%, 50 grams,
gel in a tube 20%, 100 grams.

Gel packaging includes:

aluminum tube containing the gel,
instructions for medical use,
cardboard pack.

Actovegin cream for external use:

cream in tube 5%, 20 grams,
cream in tube 5%, 30 grams,
cream in a tube 5%, 50 grams,
cream in tube 5%, 100 grams.

Cream packaging includes:

an aluminum tube containing a cream of constant white color, with no taste and smell,
instructions for medical use,
cardboard pack.

Actovegin ointment for external use:

ointment in a tube 5%, 20 grams,
ointment in a tube 5%, 30 grams,
ointment in a tube 5%, 50 grams,
ointment in a tube 5%, 100 grams.

Ointment packaging includes:

an aluminum tube containing a constant white ointment with no taste and smell,
instructions for medical use,
cardboard pack.

Actovegin solution for injections in ampoules (injections):

solution for injection 80 mg (40 mg/ml, 2 ml ampoule),
solution for injections 200 mg (40 mg/ml, 5 ml ampoule),
solution for injection 400 mg (40 mg/ml, 10 ml ampoule).

Ampoule packaging includes:

Actovegin solution for infusions:

solution for infusion in sodium chloride solution 0.9% 1000 mg (4 mg / ml, 250 ml),
solution for infusion in sodium chloride solution 0.9% 2000 mg (8 mg / ml, 250 ml),
solution for infusion in dextrose solution 1000 mg (4 mg/ml, 250 ml).

Solution packaging for infusion includes:

a colorless glass bottle (type II according to the European Pharmacopoeia) with a transparent, colorless to slightly yellow solution, corked with a cork and an aluminum cap for running in, closed on top with a lid that provides control of the first opening,
instructions for medical use,
a cardboard pack with a pasted transparent protective sticker of a round shape with holographic inscriptions and control of the first opening.

Actovegin eye gel:

gel for instillation into the eyes 20%, 5 grams.

Eye gel packaging includes:

aluminum tube containing ophthalmic gel,
instructions for medical use,
cardboard pack.

At the moment, Actovegin ophthalmic gel to Russia not supplied.

The most common forms of release and dosage of Actovegin found in pharmacies:

Tablets number 50,
Solution in 80 mg ampoules (40 mg / ml, 2 ml ampoule),
Ointment 5%, 20 grams,
Gel 20%, 20 grams.

pharmachologic effect

The pharmacological action of Actovegin is metabolic, which consists in accelerating the processes of oxygen and glucose utilization at the molecular level, thereby increasing resistance to hypoxia. The drug Actovegin has a wound-healing effect, enhances the energy state of the cell, improves blood circulation in tissues.

Indications for use Actovegin

Actovegin is indicated for use in the following diseases and conditions:

Actovegin solution for injection in ampoules and solution for infusion in sodium chloride solution additionally indicated for diabetic polyneuropathy.

Actovegin ophthalmic gel is indicated for lesions and eye diseases:

in case of damage (burns with alkali, acid) of the cornea (cornea) and sclera (protein coat),
with corneal ulcers of various etiologies,
with keratitis (inflammation of the cornea), including after corneal transplantation,
with corneal abrasion in patients using contact lenses,
in order to prevent lesions, when choosing contact lenses in patients with ongoing dystrophic processes in the cornea.

Contraindications Actovegin

The main contraindication to the use of Actovegin is hypersensitivity to the components of the drug.

Other contraindications to taking Actovegin are:

anuria (lack of urine flow to the bladder),
oliguria (reduced amount of urine excreted by the kidneys),
decompensated heart failure II and III degree,
pulmonary edema,
fluid retention in the body.

Actovegin should be taken with caution in patients with hyperchloremia (increased content of chlorine compounds in the blood) and hypernatremia (increased concentration of sodium in the blood plasma).

For Actovegin solution for infusion in a dextrose solution, an additional contraindication is diabetes mellitus - 1 vial of the drug contains 7.75 g of dextrose.

During pregnancy and lactation, the drug should be taken with caution.

Side effects of Actovegin

Side effects from taking Actovegin are extremely rare and are mainly due to hypersensitivity to the components of the drug.

Side effects of Actovegin include possible allergic reactions (, skin rash, hyperthermia (fever), up to. In such situations, treatment with Actovegin should be stopped, if necessary, use and / or.

In severe anaphylactic reactions, emergency therapy should be carried out (administer plasma substitutes, large doses, corticosteroids).

When using a gel, ointment or cream, side effects are possible in the form of itching and burning in the area of application of the drug.

At the beginning of treatment with Actovegin gel, side effects may occur in the form of local pain due to increased secretion. This side effect is not evidence of drug intolerance.

When using the eye gel, lacrimation, injection (redness) of the vessels of the sclera is possible.

If adverse reactions occur, you should stop taking Actovegin, contact a qualified medical specialist, a doctor.

Overdose of Actovegin

To date, there has been no information on an overdose of Actovegin.

Tablets Actovegin (dragee)

Actovegin tablets (pellets) are used orally (by mouth) as maintenance therapy for disorders of cerebral metabolism and circulation, to continue infusion or injection treatment for disorders of cerebral circulation.

The instruction on Actovegin tablets

Reading these instructions for the use of Actovegin tablets does not exempt the patient from studying "Instructions for the medical use of tablets (pellets) Actovegin"

Dragee should be taken orally (by mouth) before meals, without chewing, with a small amount of water.

1-2 tablets three times a day.

The duration of treatment should be 4 to 6 weeks.

The drug begins to act 30 minutes after ingestion, the maximum effectiveness occurs after 3-4 hours: the heaviness in the legs decreases, pain, tingling, numbness of the lower extremities disappear. Children and adolescents should take one tablet of Actovegin once a day, treatment continues for 28-42 days.

The frequency of taking Actovegin tablets may vary depending on the clinical picture and the severity of the disease, determined by the doctor.

Gel Actovegin

Gel Actovegin is a soft form of a drug with a viscous consistency, plasticity, elasticity, and a pH close to the pH of the skin. The gel is evenly and quickly distributed over the surface of the skin without clogging the pores.

Actovegin gel is applied topically under the following circumstances and pathologies:

Actovegin gel is also used for the prevention and treatment of bedsores.

Instructions for Actovegin gel

Reading these instructions for the use of Actovegin gel does not exempt the patient from studying "Instructions for the medical use of Actovegin gel" in the manufacturer's carton.

When treating open wounds and ulcers, Actovegin gel should be applied in a thin layer to the affected areas 5-6 times a day.

When performing pre-treatment to clean ulcerative lesions, the gel must be applied in a thick layer, covering Actovegin ointment with a compress, or with a gauze bandage soaked in ointment (to prevent sticking to the wound). The bandage should be changed once every 24 hours, in the treatment of heavily weeping surfaces - 3-4 times a day. Further treatment should be continued with Actovegin in the form of a cream; treatment should be completed with Actovegin in the form of an ointment.

For burns and radiation injuries, the gel should be applied to the skin in a thin layer.

In the treatment of radiation injuries in patients, the remedy is used in the form of applications.

For the prevention and treatment of bedsores, Actovegin gel must be used 3-4 times a day, the course of treatment is from 3 to 60 days.

The frequency of application of the gel may vary depending on the clinical picture and the severity of the disease, determined by the doctor.

Cream Actovegin

Actovegin cream is applied topically under the following circumstances and pathologies:

with ulcers of varicose origin, weeping ulcers,
with wounds and inflammation of the skin and mucous membranes, burns, skin cuts, scratches, abrasions,
in order to promote tissue regeneration after burns,
during pre-treatment of wound surfaces before transplantation,
for the prevention and treatment of mucosal and skin reactions caused by exposure to radioactive radiation.

Actovegin cream is also used for the prevention and treatment of bedsores.

Instructions for Actovegin cream

Reading these instructions for the use of Actovegin cream does not relieve the patient from studying "Instructions for the medical use of Actovegin cream" in the manufacturer's carton.

Actovegin cream should be used to accelerate the healing of wounds, including wounds with discharge (weeping ulcers).

Remedy applied at the second stage three-stage therapy with Actovegin after applying the gel. The cream is applied in a thin layer 2-3 times a day.

To prevent bedsores, Actovegin cream should be rubbed into the skin in high-risk areas.

When preventing the occurrence of radiation injuries, the agent should be applied in a thin layer immediately after radiation therapy, in the intervals between sessions.

The frequency of use of Actovegin cream may vary depending on the clinical picture and the severity of the disease, determined by the doctor.

After the first opening of the package, the drug should be used within four weeks.

Actovegin ointment is applied topically under the following circumstances and pathologies:

with wounds and inflammation of the skin and mucous membranes, burns, skin cuts, scratches, abrasions,
in order to promote tissue regeneration after burns,
with ulcers of varicose origin, weeping ulcers,
for the prevention and treatment of mucosal and skin reactions caused by exposure to radioactive radiation,
during pre-treatment of wound surfaces before transplantation,

Also, the ointment is used for the prevention and treatment of bedsores.

The instruction on Actovegin ointment

Reading these instructions for use of Actovegin ointment does not exempt the patient from studying "Instructions for the medical use of Actovegin ointment" in the manufacturer's carton.

Actovegin ointment should be used for long-term three-stage treatment of wounds and ulcers to accelerate and / or chemotherapeutic agents (mainly sulfonamides), antiseptics). The rate of administration is ~2 ml/min.

Do not use an opaque solution or a solution containing foreign particles. After opening the vial (ampoule), the solution can not be stored.

With intramuscular injections of Actovegin, the drug is administered slowly, not more than 5 ml. Due to the risk of an anaphylactic reaction, a test injection (2 ml per minute) is recommended.

After 30-40 minutes after using the product, an increase in body temperature, the appearance of rashes is possible. In such a situation, it is necessary to stop the course of treatment.

Actovegin solution for infusions

Actovegin 10% or 20% infusion (with or without glucose) solution is intended for intravenous or intra-arterial infusions. Actovegin infusion solution has a slightly yellowish tint. The color intensity may vary depending on the characteristics of the starting materials used, but does not adversely affect the activity of the drug or its tolerability.

The solution for infusion is used parenterally under the following circumstances:

with violations of the peripheral (venous and arterial) circulation, their consequences in the form of leg ulcers, arterial angiopathy,
in violation of cerebral metabolism and blood circulation (traumatic brain injury, ischemic stroke, cerebral insufficiency syndrome),
with complications arising from wound healing (pressure sores, poorly healing wounds),
with burns, ulceration of the skin,
in skin transplantation,
as a means of prevention and treatment of radiation damage to the skin, mucosa, and nervous tissue.

Instructions for the solution for infusion Actovegin

Reading these instructions for use of the solution for infusion Actovegin does not exempt the patient from studying "Instructions for the medical use of Actovegin infusion solution" in the manufacturer's carton.

Before using the solution, make sure that the vial is intact.

As a rule, the solution for infusion is used in a volume of 250 ml per day, intravenously or intra-arterially. The infusion rate should be ~2 ml/min. 10-20 infusions may be required to achieve maximum effect. It is allowed to increase the initial dose of 10% solution up to 500 ml.

When carrying out infusions, it is important to ensure that the solution does not enter extravascular tissues.

It is not allowed to add other drugs to the infusion solution of Actovegin.

Due to the risk of developing anaphylactic reactions, it is recommended to test for the presence of hypersensitivity to the drug before infusion.

In case of violation of blood supply and metabolism of the brain, the dosage is:

Initially, 250-500 ml (1000-2000 mg of the drug) intravenously per day for 2 weeks (with subsequent transition to the tablet form),
Further, 250 ml intravenously 3-4 times a week (for Actovegin infusions in dextrose solution) for 30 days or more.

In case of ischemic stroke, the administration of Actovegin infusion solution is carried out in 250-500 ml intravenously daily or several times a week for 14 days, followed by the transition to a tablet form.

In case of arterial angiopathy, it is necessary to inject 250 ml (1000 mg) intra-arterially and intravenously daily or several times a week for four weeks, followed by the transition to a tablet form (for infusions in sodium chloride solution),

With Ulcus cruris (varicose ulcer of the leg), other sluggish ulcers, burns, the solution for infusion should be administered 250 ml (1000 mg of the drug) intravenously daily or several times a week, depending on the healing rate, in addition to local therapy with Actovegin.

In case of diabetic polyneuropathy, 250-500 ml of solution for infusion in sodium chloride solution should be administered intravenously daily for three weeks, followed by the transition to a tablet form (2-3 tablets three times a day for 4-5 months).

In the prevention and treatment of radiation damage to the skin and mucous membranes, 250 ml (1000 mg of the drug) is administered intravenously one day before it starts, daily during radiation therapy, for two weeks after it ends, followed by a transition to a tablet form. The rate of administration is ~2 ml per minute.

With repeated injections of Actovegin infusion solution, it is necessary to control the water and electrolyte balance of the blood plasma.

Do not use an opaque solution or a solution containing foreign particles.

The frequency, dose, method of administration of the solution may vary depending on the clinical picture and the severity of the disease, determined by the doctor.

Eye gel Actovegin

Eye gel Actovegin is applied topically for injuries of the cornea of the eye:

burns
inflammation of various origins,
in corneal transplantation in the preoperative and postoperative periods,
in patients with defects in the corneal epithelium due to wearing contact lenses.

Eye gel Actovegin is used for prophylactic selection of contact lenses in patients with impaired corneal trophism (atrophic and dystrophic processes), with age-related atrophic inflammation of the cornea.

Instructions for eye gel Actovegin

Reading these instructions for the use of Actovegin eye gel does not exempt the patient from studying "Instructions for the medical use of Actovegin ophthalmic gel" in the manufacturer's carton.

Eye gel should be applied to the diseased eye 1-3 times a day, 1-2 drops. When using the product, there may be an increased secretion of secretion, causing discomfort and pain.

The frequency and duration of application of the eye gel may vary depending on the cause and severity of the disease, determined by the attending physician.

After the first opening of the package, the drug should be used within four weeks.

Actovegin during pregnancy

Actovegin during pregnancy is prescribed to women who have already had a miscarriage (spontaneous abortion) to maintain the health of the fetus, further stable pregnancy.

An extract from the blood of young calves is the main element of Actovegin. The medicine promotes the accumulation and transport of glucose, oxygen in the body of a pregnant woman, and improves cell metabolism. Actovegin in pregnant women improves blood circulation, increases the energy reserves of cells and accelerates metabolic processes. The action of the drug begins after 15-30 minutes from the moment of administration. Before taking Actovegin, a pregnant woman should consult a doctor.

Actovegin is prescribed for pregnant women if the following complications occur:

If side effects occur, it is necessary to interrupt the course of treatment, consult a medical specialist.

At the moment, there have been no cases of negative effects of Actovegin on the fetus and the body of a pregnant woman in medicine.

When using the drug in pregnant women, it is necessary to take into account the potential risk to the fetus.

During breastfeeding, there are no contraindications against taking the drug.

Actovegin for children

Actovegin is prescribed for children (usually in tablets) for traumatic brain injuries, metabolic disorders, and circulatory disorders of the brain.

Actovegin is used in ophthalmology for the treatment of children with damage to the cornea of the eye, in the presence of burns, ulcers, abrasions, bedsores, and long-term healing wounds.

Actovegin is an extract from the blood of calves. Due to the physiological basis of the drug, the risk of side effects in children is minimal.

Actovegin is produced in the form of ointment, tablets, gel, cream and ampoules (injections). Depending on the type of disease, the duration of the course of the disease, the doctor prescribes the necessary type of medicine. Appointment of Actovegin to children is different from the use of this drug by adults.

The remedy in tablets is prescribed one piece once a day or half twice a day.

Actovegin injections for newborns are prescribed at a dose of 0.4-0.5 ml / kg once a day intramuscularly, for children aged one to three years - 0.4-0.5 ml / kg, three to six years - 0.25 -0.4 ml/kg once a day.

Before starting systematic injections of Actovegin in children, it is necessary to carry out a trial administration. Side effects of the drug are extremely rare, due to extreme sensitivity to individual components of the drug. Complications are manifested in the form of fever, skin hyperemia, urticaria. With such phenomena, it is necessary to stop taking the medicine, consult a doctor for symptomatic therapy.

Actovegin for atherosclerosis

The use of Actovegin in atherosclerosis avoids complications, surgical intervention. In atherosclerosis, the drug is initially used in the form of injections, then in the tablet form of the drug.

The formation of plaques in atherosclerosis occurs in the aorta, in medium and small arteries. During exercise, muscles require a significant amount of oxygen. Narrowed arteries impede blood supply, as a result, painful sensations arise. With a disease of the arteries of the lower extremities, a person constantly experiences pain, as a result, he needs constant stops, is not able to overcome significant distances on his own.

As a result of poor nutrition and oxygen supply, ischemic changes develop - ulcers and necrosis appear. With a long course of the disease and the absence of adequate treatment, a complete blockage of the vessel occurs, requiring an emergency surgical operation to prevent the development of gangrene. After completing the course of treatment with Actovegin for atherosclerosis, a person gets the opportunity to move more without feeling pain and spasms in the legs. In complex therapy, Actovegin improves microcirculation, has a positive effect on the transport and absorption of glucose, and stimulates the uptake of oxygen by cells.

The course use of Actovegin in patients with chronic obliterating diseases (diseases of the arteries of the lower extremities) involves intravenous injections of 800-1000 mg - from 14 to 28 days, then 200 mg tablets 1-2 tablets 3 times a day for 30 days, as a result it decreases pain syndrome, including when walking.

Actovegin for the brain

Actovegin for the brain is used for cerebrovascular insufficiency - a chronic circulatory disorder of the brain against the background of arterial hypertension, heart disease, venous pathology, atherosclerosis.

With these complications, the brain is constantly in conditions of oxygen and energy deficiency, its normal functioning is disrupted. High blood pressure is a factor that provokes these disorders.

Actovegin is a neuroprotector that protects neurons from ischemia (insufficient blood supply to the organ), ensures the delivery of oxygen and glucose to neurons, satisfies the energy needs of the brain in conditions of "oxygen starvation". Due to the combination of antioxidant and antihypoxic properties, the action of the drug slows down pathological processes in the brain, provides regeneration (restoration) of damaged neurons and brain functions.

After completing a course of antihypertensive therapy together with Actovegin, neurological symptoms, memory, ability to concentrate improve, headaches, insomnia stop, working capacity returns, vitality, mood normalizes.

In chronic cerebrovascular insufficiency, tablets and ampoules of Actovegin 10 ml should be taken, initially injections for 10 days. After a course of injections, take 1-2 tablets of the drug 3 times a day, before meals, drinking plenty of water. It must be taken within 1-2 months.

Actovegin for varicose veins

An important mechanism for the development of varicose veins (venous insufficiency) is a violation of microcirculation and a violation of the functions of the endothelium of venous vessels. With varicose veins, Actovegin provides an antihypoxic effect, improves cell metabolism and microcirculation parameters, accelerates healing and epithelization in trophic ulcers. The complex action of Actovegin reduces symptoms (pain, swelling, "heavy legs syndrome"), prevents the progressive development of venous insufficiency.

Actovegin for bedsores

In the treatment of bedsores, all three forms of Actovegin for topical use (gel, cream and ointment) are used. It is allowed to use the drug in combination with other means (solutions of antiseptics).

In the stage of inflammation (first-fourth day), a twenty percent gel is applied to the wound, protecting it from infection. In the stage of granulation (formation of temporary tissue) on the first to fourteenth day, the wound surface of the bedsore is treated with a five percent cream. After the cessation of wet secretions and the beginning of epithelization (fourth to seventeenth days), Actovegin 5% ointment is applied. The combined use of all three forms of the drug contributes to faster and more active tissue regeneration.

Actovegin in diabetes mellitus

Actovegin in diabetes mellitus does not replace and does not compete with hypoglycemic therapy, it complements it. Actovegin saturates cells with glucose, without the risk of causing a sharp decrease in blood sugar. In effective therapeutic dosages, Actovegin does not cause the risk of hypoglycemia.

Blood glucose (blood sugar, glycemia) is the most important controlled variable in humans (homeostasis). The level of blood glucose is controlled by several physiological processes: it rises after a meal, it decreases due to catabolism, stress, physical exertion. In diabetes, blood glucose levels remain constantly high.

Against the background of hyperglycemia in patients with diabetes mellitus, sugar in the urine (glucosuria) is detected.

Sugar in the urine (glucose in the urine, glucosuria, glycosuria) is a laboratory term meaning the presence of sugar in the urine in excess of physiologically justified values. The kidneys are able to return to the bloodstream the entire volume of glucose that has passed through the renal glomerulus. Normally, in a healthy person, glucose in the urine is contained in small volumes (0.06 - 0.083 mmol / l), insufficient for determination in the laboratory.

The body, having lost the main source of energy, compensating for the deficiency, begins to secrete large amounts of hormones that mobilize fats, and primarily adrenaline and adrenocorticotropic hormone (ACTH). Under the influence of these hormones, endogenous fats (fats synthesized in the liver from carbohydrates) are intensively decomposed, and exogenous fats (fats from food) are not sufficiently utilized, which is accompanied by the synthesis of ketone bodies (acetone) in the liver, followed by excretion from the body with urine.

Acetone in the urine is a laboratory term meaning the detection of acetone in the urine in excess of physiologically justified values. Normally, in a healthy person, acetone is not detected in the urine, since it is utilized by the body, excreted with exhaled air, and in extremely small concentrations it can be excreted in the urine.

A systematic increase in sugar (glucose) with prolonged diabetes mellitus leads to disturbances in the functioning of the central nervous system. The nerves receive nutrition from the blood vessels, in diabetes mellitus, this process is disrupted due to oxygen starvation, the first symptoms of peripheral nerve damage appear - polyneuropathy. Damage to the nerves in diabetes mellitus leads to severe pain, impaired sensitivity, muscle cramps.

Diabetic polyneuropathy is one of the most common complications of diabetes mellitus, which significantly worsens the patient's quality of life, leading to the development of diabetic foot syndrome. The use of Actovegin in patients with diabetes mellitus improves the energy metabolism of tissues, increases the resistance of cells to ischemia and hypoxia, improves the transport and absorption of glucose, positively affecting the development of neurological symptoms.

Numbness of the legs in the evening is the first alarming symptom of the future occurrence of diabetic foot syndrome (ulcer-necrotic lesions of the skin, soft tissues, in severe cases, the bone tissue of the foot). With a decrease in sensitivity and insufficient blood supply, the healing process of microtraumas and calluses slows down, as a result, gangrene develops. Taking Actovegin in diabetes mellitus in combination with hypoglycemic therapy and diet compensates for the disease and prevents its complications. Under the action of Actovegin in diabetes mellitus, pain, paresthesia (goosebumps, numbness), cracks, ulcers disappear. The use of Actovegin (local and systemic forms) restores blood circulation in the ischemic zone, accelerates tissue regeneration in patients with ulcerative defects, improves microcirculation processes, endothelial function.

Wound healing in gangrene is achieved when blood glucose levels return to normal. The stimulating effect of the drug on wound healing is due to improved glucose utilization, regardless of the genesis (origin) of the wound, and even in the presence of resistance (resistance) to insulin.

Actovegin's analogs

The analogue (synonym) of Actovegin for the active substance is the drug Solcoseryl, manufactured by the pharmaceutical company Solco, Switzerland. Actovegin differs from its counterpart in an extended shelf life.

Price Actovegin

The price of Actovegin tablets, gels, ointments, creams, ampoules and solutions does not include delivery costs if the drug is purchased through an online pharmacy. Prices can vary significantly depending on the place of purchase, dosage and form of release.

The cost of Actovegin:

Russia (Moscow, St. Petersburg) from 109 to 2150 Russian rubles,
Ukraine (Kyiv, Kharkov) from 36 to 710 Ukrainian hryvnias,
Kazakhstan (Almaty, Temirtau) from 513 to 10127 Kazakhstani tenge,
Belarus (Minsk, Gomel) from 28667 to 565450 Belarusian rubles,
Moldova (Chisinau) from 31 to 602 MDL,
Kyrgyzstan (Bishkek, Osh) from 119 to 2344 Kyrgyz soms,
Uzbekistan (Tashkent, Samarkand) from 4227 to 83377 Uzbek soums,
Azerbaijan (Baku, Ganja) from 1.6 to 32.0 Azerbaijani manats,
Armenia (Yerevan, Gyumri) from 749 to 14771 Armenian drams,
Georgia (Tbilisi, Batumi) from 3.7 to 73.1 Georgian lari,
Tajikistan (Dushanbe, Khujand) from 10.3 to 202.5 Tajik somoni,
Turkmenistan (Ashgabat, Turkmenabat) from 5.3 to 103.8 new Turkmen manats.

Buy Actovegin

You can buy Actovegin in the form of tablets, gel, ointment, cream, in ampoules for injection, infusion solution at a pharmacy using the drug reservation service, including. Before you buy Actovegin, you should clarify the expiration dates. You can order Actovegin at any available online pharmacy, the sale is carried out with home delivery by courier, upon presentation of a doctor's prescription.

Producer Actovegin

The manufacturer of Actovegin is the pharmaceutical company Nycomed (Switzerland), which is part of Takeda Pharmaceutical (Japan). In Russia, Actovegin is produced at the Sotex Pharmaceutical Company, owned by Protek.

Takeda Pharmaceutical Company Limited (武,田,«220,Ø97,ð37,業,株,ó35,Ê50,社,) is the largest Asian pharmaceutical company, one of the 15 largest in the world. Takeda's areas of interest include: metabolic, respiratory, cardiovascular diseases, gastroenterology, immunology, neurology, oncology. Nycomed was acquired by Takeda in 2011 for 9.6 billion euros. Takeda's largest US partner is Eli Lilly.

Eli Lilly is an American pharmaceutical company that produces drugs used in oncology, psychiatry, neurology, cardiology, and urology. Eli Lilly became the first company to mass-produce drugs used in the treatment of diabetes in the twenties of the 20th century (in particular, insulins under the Iletin trademark).

Storage Actovegin

Actovegin should be stored in a dry place, protected from light, out of the reach of children, at a temperature of +5 to +25 °C. It is not guaranteed that the medicinal properties of the drug will be preserved in case of violation of storage conditions, at a temperature regime that differs from that recommended by the manufacturer. Freezing of the drug is not allowed.

The shelf life of Actovegin is:

Tablets (drops) - 36 months from the date of release of the drug,
Gel - 36 months from the date of release of the drug,

Packing photo Actovegin cream 5% 20 grams.

Packing photo Actovegin ampoules 5 ml.